Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov-Dec;4(6):374-8.
doi: 10.4161/bioe.23573. Epub 2013 Jan 21.

Development of a universal CTL-based vaccine for influenza

Diego Esteban Cargnelutti  1 , María Victoria Sánchez  2 , Nora Marta Mattion  3 , Eduardo Alberto Scodeller  2
Affiliations
Review

Development of a universal CTL-based vaccine for influenza

Diego Esteban Cargnelutti et al. Bioengineered. 2013 Nov-Dec.

Abstract

In pursuit of better influenza vaccines, many strategies are being studied worldwide. An attractive alternative is the generation of a broadly cross-reactive vaccine based on the induction of cytotoxic T-lymphocytes (CTL) directed against conserved internal antigens of influenza A virus. The feasibility of this approach using recombinant viral vectors has recently been demonstrated in mice and humans by several research groups. However, similar results might also be achieved through immunization with viral proteins expressed in a prokaryotic system formulated with the appropriate adjuvants and delivery systems. This approach would be much simpler and less expensive. Recent results from several laboratories seem to confirm this is as a valid option to be considered.

Keywords: adjuvants; cellular immunity; cross-presentation; cytotoxic-T-lymphocytes; influenza vaccines; recombinant antigen.

PubMed Disclaimer

References

    1. Osterhaus A, Fouchier R, Rimmelzwaan G. Towards universal influenza vaccines? Philos Trans R Soc Lond B Biol Sci. 2011;366:2766–73. doi: 10.1098/rstb.2011.0102. - DOI - PMC - PubMed
    1. Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother. 2012;8:45–58. - PubMed
    1. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:36–44. doi: 10.1016/S1473-3099(11)70295-X. - DOI - PubMed
    1. Quan FS, Compans RW, Kang SM. Oral vaccination with inactivated influenza vaccine induces cross-protective immunity. Vaccine. 2012;30:180–8. doi: 10.1016/j.vaccine.2011.11.028. - DOI - PMC - PubMed
    1. Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, et al. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol. 2012;19:979–90. doi: 10.1128/CVI.00016-12. - DOI - PMC - PubMed